The Cannabis Community

11/07/2026

More Americans are testing positive for ma*****na in workplace drug tests, raising questions among employers over their usefulness in screening job candidates. 🔗 https://on.wsj.com/4yl1qd0

As legalized ma*****na spreads, its growing use is showing up in drug tests at some of the highest rates in years, according to new data from Quest Diagnostics, which conducted about eight million workforce drug tests in 2025. The share of urine tests that came back positive for the substance rose to 4.4% last year, up from 3.9% in 2021.

Hair tests, a less common method that can detect drug use much further back, as much as 90 days before, showed more widespread use. About 15% of workers screened that way tested positive for ma*****na, a nearly 60% jump from 2021. Random screenings were even higher at 21%.

With so many working Americans now using the drug—at least occasionally—testing positive is no longer the deal breaker to getting or keeping a job it once was. Outside of trucking, construction and other safety-sensitive industries, more employers say they have come to view ma*****na as akin to alcohol: not a red flag, as long as workers aren’t indulging on the clock.

And fewer employers are screening job candidates for ma*****na use at all, in part because it would make it tougher to find enough qualified candidates, said Todd Logsdon, a partner at employment law firm Fisher Phillips.

“I’ve had other employers tell me, ’If I test for that, I’m not gonna have any applicants,’” Logsdon said. “They’re being very choosy about which role they test for.”

18/06/2026

16/06/2026

Illinois just passed one of its most important cannabis reform packages since adult-use legalization.

SB 3222 does more than address intoxicating h**p products. It creates the Illinois H**p Act, expands medical cannabis access, updates oversight, supports social equity operators, and sets the stage for a new implementation fight across the industry.

We broke down what the law actually changes, who it affects, and what operators, patients, h**p retailers, and advocates should be watching next.

Read the full article:

Illinois SB 3222 rewrites cannabis and h**p rules, regulating intoxicating h**p, expanding medical access and updating social equity oversight.

27/04/2026

Every major outlet covering the April 23rd Schedule III order is asking the same question: what does this mean for the cannabis industry?

We think that's the wrong question...or at least, not the only one that matters.

Because while investors are calculating what this means for multi-state operators, and lawyers are debating what it means for interstate commerce, there's a much larger group of people who just want to know: does any of this actually change my life as someone who uses medical cannabis?

That's the question we set out to answer. And the truth is, the answer isn't simple, but it is knowable, and you deserve to know it.

Here's a preview of what the article covers:
❓ Can you travel with your medical cannabis now that it's in Schedule III? (The answer is still no, and here's why)
❓ Will prices at your dispensary actually go down, and if so, when? (There's real reason for optimism here because the 280E tax story is significant)
❓ Are you protected on federal land? At your federally assisted housing? At your job?
❓ What does this mean for gun rights — one of the most important and underreported issues for cannabis patients?
❓ What about immigration status?
❓ Will doctors finally be able to actually prescribe cannabis instead of just recommending it?
❓ What happens if the courts step in and block the order entirely (which is a very real possibility)?
❓ What's the best case and worst case scenario 12 months from now?

We got every one of these questions answered by cannabis attorney Jason C. Adelstone, a nationally recognized expert on U.S. and international drug treaty law — and the same attorney we interviewed back in December who correctly predicted exactly how this rescheduling would happen. He called his shot. We called him the day the order was signed.

🙏 A sincere thank you to Jason for his time, his honesty, and his continued commitment to making sure patients — not just the industry — understand what's happening with the laws that affect their lives.

This is the breakdown you won't find anywhere else, written for the people who actually use cannabis , not just the industry.

Read it now at https://www.thecannabiscommunity.org/schedule-iii-executive-order-medical-cannabis-patients/

*****na

Attorney Jason Adelstone breaks down the April 23rd Schedule III order — what changed, who's covered, and what patients need to know right now.

19/03/2026

Tough times in Illinois 😬

Chicago’s Green Thumb Industries reported $114.1 million in net income last year, making it a stark outlier in an Illinois cannabis market where competitors continue to hemorrhage cash.

Five of the so-called multistate operators in Illinois — New York-based Ascend Wellness, Connecticut-based Curaleaf, Massachusetts-based MariMed, and Chicago-based Cresco Labs and Verano Holdings — lost a cumulative $761 million last year, underscoring the strain for an industry facing regulatory uncertainty.

Ascend, Cresco, Curaleaf and Verano each have 10 dispensaries in Illinois, while MariMed has five. Outlier GTI has 12 dispensaries in Illinois and a national footprint in 14 states.

As of today, three other multistate cannabis companies that operate in Illinois — The Cannabist Company, Jushi and Planet 13 — had not yet reported their fourth quarter financials, but all three previously reported millions in ongoing losses. The Cannabist has two ma*****na shops in Illinois, Jushi owns five and Planet 13 has one in Waukegan.

Read more here: https://www.chicagobusiness.com/cannabis/ccb-cannabis-losses-2025/?utm_source=facebook&utm_medium=soc-own